ISRCTN18128181进行中（未招募）未知
An open-label, multi-centre, randomised controlled trial evaluating the effects of short-course rifapentine-based regimens and additional adherence support on LTBI treatment adherence and completion among adults in the UK
niversity College London0 个研究点目标入组 920 人开始时间: 2022年5月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 920
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged > = 16 years to < = 65 at screening
- •2. LTBI diagnosis is defined on the basis of all of the following:
- •2.1. A positive result on an Interferon Gamma Release Assay (IGRA), Tuberculin Skin Test (TST) or C-Tb skin test and
- •2.2. Negative TB symptoms at screening and
- •2.3. No signs of active TB on a Chest X-ray
- •3. Eligible for LTBI treatment at TB clinics and national LTBI screening services based on NICE guidelines, which means having one or more of the following :
- •3.1. Recent infection (contact tracing);
- •3.2. New entrants at risk (i.e., those that immigrated < 5 years from countries with a high incidence of TB, which is defined as > = 40 cases/100,000 population); or
- •3.3. Individuals who are assessed in the TB clinic for latent TB testing, or have been referred for treatment following testing by specialities or departments within primary or secondary care settings
- •4. Agree to LTBI treatment
- •5. Willing and able to provide written informed consent
排除标准
- •1. Patients weighing < 30 kg.
- •2. Need for medications that cannot be safely taken together with study drugs
- •3. Any medical condition deserving priority of treatment (such as: porphyria, malabsorption syndromes, Clostridium difficile-associated diarrhoea and other conditions)
- •4. History of sensitivity/intolerance to isoniazid or rifamycins
- •5. Individuals with documented liver disease, defined as:
- •5.1. LFT (ALT/AST/bilirubin) over three times upper limit of normal (ULN) at baseline. This reflects normal clinical practice. For patient participant safety, liver function tests are carried on a regular basis. One abnormal value prevents the patient from participating on the study.
- •5.2. Clinical diagnosis of cirrhosis (jaundice, hematemesis, ascites or previous episodes of liver encephalopathy),
- •5.3. HbsAg positive or HCV antibody positive and deemed ineligible for LTBI treatment by the clinician
- •6. Intending to move outside of the treatment locality within 20 weeks of starting treatment
- •7. Individuals who would usually be offered LTBI treatment under Directly Observed Therapy (DOT) as part of enhanced case management in complex cases such as those from under-served groups (such as people who are homeless, misuse substances, have been in prison or who are vulnerable migrants).
- •8. Use of another experimental investigational medicinal product that is likely to interfere with the study medication within 3 months of study enrolment.
- •9. Women who are breastfeeding, pregnant, or of childbearing potential* who do not agree to use an effective method of contraception from the time consent is signed until 4 weeks after treatment discontinuation or completion.
- •10. Women of childbearing potential without a negative urine pregnancy test within 7 days prior to being registered for trial treatment.
研究者
相似试验
进行中（未招募）
1 期
Research to Improve the Detection and Treatment of Latent Tuberculosis Infection: TreatmentEUCTR2020-004444-29-GBniversity College London920
已完成
不适用
A randomised, controlled, multi-centre open-label study in healthy Japanese subjects to evaluate the effect on biomarkers of exposure of switching from a conventional combustible cigarette to the glo tobacco heating product.Cigarette smokingJPRN-UMIN000024988British American Tobacco (Investments) Limited180
招募中
2 期
Efficacy and safety of a carbohydrate-counting smartphone application in type 1 diabetesGlucose, insulin treatment, insulin secretionType 1 diabetesJPRN-jRCTs042210167Chujo Daisuke56
招募中
不适用
A multi-center, open-label, randomized controlled clinical trial study on the treatment of Delta novel coronavirus pneumonia (COVID-19) based on ''three-party'' syndrome differentiation and treatmentDelta Novel Coronavirus PneumoniaITMCTR2100005149Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Province Hospital of Chinese Medicine)
进行中（未招募）
1 期
A clinical trial where a change in medication can reduce the incidence of diabetes after renal transplantation.Prophylaxis of rejection in kidney allograft recipients (by immunosuppression)MedDRA version: 14.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2012-000451-13-SETransplant Institute, Sahlgrenska University Hospital223